Kymera Therapeutics (KYMR) EPS (Weighted Average and Diluted): 2020-2025
Historic EPS (Weighted Average and Diluted) for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to -$0.94.
- Kymera Therapeutics' EPS (Weighted Average and Diluted) fell 14.63% to -$0.94 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.60, marking a year-over-year decrease of 53.85%. This contributed to the annual value of -$2.98 for FY2024, which is 18.25% down from last year.
- Kymera Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.94 in Q3 2025, which was up 1.05% from -$0.95 recorded in Q2 2025.
- In the past 5 years, Kymera Therapeutics' EPS (Weighted Average and Diluted) registered a high of -$0.25 during Q4 2023, and its lowest value of -$0.95 during Q2 2025.
- Its 3-year average for EPS (Weighted Average and Diluted) is -$0.75, with a median of -$0.82 in 2025.
- As far as peak fluctuations go, Kymera Therapeutics' EPS (Weighted Average and Diluted) skyrocketed by 57.63% in 2023, and later tumbled by 256.00% in 2024.
- Over the past 5 years, Kymera Therapeutics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.67 in 2021, then climbed by 11.94% to -$0.59 in 2022, then surged by 57.63% to -$0.25 in 2023, then plummeted by 256.00% to -$0.89 in 2024, then declined by 14.63% to -$0.94 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.94 for Q3 2025, versus -$0.95 for Q2 2025 and -$0.82 for Q1 2025.